Lyell Immunopharma (LYEL) SEC Filings: History & Chart

Lyell Immunopharma, Inc.(LYEL)

Biotechnology · South San Francisco, CA

$8.61-0.46 (-5.07%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lynn Seely

View full financials

Form	Filing Date	Accepted	Document
4	Sep 10, 2026	Sep 10, 2026	View filing
4	Sep 10, 2026	Sep 10, 2026	View filing
3	Sep 10, 2026	Sep 10, 2026	View filing
8-K	Sep 10, 2026	Sep 10, 2026	View filing
4	Aug 25, 2026	Aug 25, 2026	View filing
4	Aug 25, 2026	Aug 25, 2026	View filing
4	Aug 25, 2026	Aug 25, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
4	Aug 11, 2026	Aug 11, 2026	View filing
4	Aug 11, 2026	Aug 11, 2026	View filing
4	Aug 11, 2026	Aug 11, 2026	View filing
4	Aug 11, 2026	Aug 11, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
4	Jul 27, 2026	Jul 27, 2026	View filing
4	Jul 27, 2026	Jul 27, 2026	View filing
EFFECT	Jul 21, 2026	Jul 22, 2026	View filing
4	Jul 20, 2026	Jul 20, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
S-3	Jul 13, 2026	Jul 13, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
SC 13G/A	Jun 18, 2026	Jun 18, 2026	View filing
3	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing

SEC Filings

Recent Filings